Computational Drug Discovery Market Size, Share, Trends, and Growth Forecasts, 2026-2031 Report Released; Analysts Predict Computational Drug Discovery Market to Reach USD 6.47 Billion by 2031 as AI Adoption Accelerates

Computational Drug Discovery Market Size, Share, Trends, and Growth Forecasts, 2026-2031 Report Released; Analysts Predict Computational Drug Discovery Market to Reach USD 6.47 Billion by 2031 as AI Adoption Accelerates Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Computational Drug Discovery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global computational drug discovery market is expected to grow from USD 2.79 billion in 2025 and USD 3.15 billion in 2026 to USD 6.47 billion by 2031, registering a CAGR of 15.49% from 2026 to 2031. Market growth is being supported by rising pharmaceutical R&D costs, rapid advances in AI/ML and generative chemistry, expanding cloud/SaaS adoption, and increasing regulatory acceptance of model-informed drug-development methods.

Rising R&D Costs Drive In-Silico Drug Discovery Adoption

Per-drug R&D costs exceeded USD 2.6 billion in 2024, while Phase II oncology success rates remained near 8%. These pressures are encouraging pharmaceutical and biotechnology companies to identify weak candidates earlier and reduce costly late-stage failures. Virtual discovery workflows can shorten target-to-candidate timelines from approximately six years to less than two years, enabling faster and more cost-effective development decisions.

Eli Lilly's USD 2.75 billion agreement with Insilico Medicine demonstrates the commercial potential of this approach. The collaboration advanced Rentosertib into Phase IIa within 30 months. Contract research organizations are also increasingly requiring ADME/Tox predictions before wet-lab studies, helping reduce preclinical attrition by as much as one-third and potentially saving USD 1-3 million per program.

Investment patterns are reinforcing this shift. With venture funding for traditional biotech Series A rounds declining 40% in 2025, investors are showing greater interest in asset-light AI drug discovery models that can scale without extensive laboratory infrastructure.

AI/ML and Generative Chemistry Expand Discovery Capabilities

Advances in AI/ML, generative AI, and accelerated computing are increasing screening capacity and improving molecular design. DrugCLIP can screen 10 trillion protein-molecule pairs daily, reducing processes that previously required months to a matter of hours. Isomorphic Labs' IsoDDE has reported 2.3-fold higher antibody-antigen accuracy than AlphaFold3, supporting design workflows that do not depend on crystal structures.

AstraZeneca's MapDiff has reduced the cycle between virtual hit identification and synthesized analog development, while H100-based GPU clusters have shortened model-training periods for Genesis Therapeutics from 18 months to six months. Latent Labs' antibody platform has also accelerated affinity maturation iterations by 56 times compared with hybridoma-based methods. Collectively, these advances allow drug developers to evaluate broader pipelines while lowering costs per program.

Infrastructure Costs and Talent Shortages Remain Key Challenges

High-performance computing requirements continue to restrict adoption among mid-size biotechnology companies and academic institutions. A fit-for-purpose computing cluster can cost USD 2-5 million to build and an additional USD 0.5-1 million annually to operate. Cloud access can reduce initial investment, although pricing in emerging economies may be 20-30% higher than U.S. rates because of limited data-center capacity.

The shortage of professionals with combined AI and medicinal-chemistry expertise is another significant constraint. Fewer than 10,000 such specialists are available globally, with salaries exceeding USD 200,000 in major life sciences hubs. Fewer than 50 universities currently offer dedicated AI-drug-discovery programs, leaving annual graduate output well below the estimated demand for 5,000 specialists. Data silos, limited interoperability across multi-omics datasets, and long academic computing queues also continue to affect implementation.

Software/AI Platforms Lead Market Revenue

Software/AI platforms accounted for 59.58% of computational drug discovery market revenue in 2025 and are projected to expand at a CAGR of 17.24% through 2031. Their leadership reflects pharmaceutical companies' growing preference for controlling core algorithms, proprietary data, and internal discovery workflows. Services remain important for smaller sponsors seeking turnkey programs, but cloud-native pricing is reducing the cost advantages traditionally associated with outsourced models.

Platform providers are increasingly bundling model updates, compliance resources, and user training into subscription offerings. Certara's Simcyp package, re-launched in 2025, includes automatic PBPK template updates and on-demand webinars designed to support ICH M15 traceability requirements. This shift is narrowing the distinction between software products and services while encouraging customers to develop internal capabilities rather than rely on long-term outsourcing.

Lead Discovery Gains Momentum

Target identification and validation represented 56.53% of market spending in 2025. However, lead discovery is forecast to grow at a CAGR of 16.82%, supported by ultra-large virtual screening and faster hit-identification. DrugCLIP's screening capacity can reduce hit-identification timelines from six months to less than one week, accelerating medicinal chemistry programs.

These technologies are also improving fragment expansion for rare-disease targets that were previously considered commercially challenging. PyRMD2Dock achieved a 7.3% sub-micromolar hit rate against CD28, indicating that algorithmic screening can approach the quality of physical high-throughput screening at a lower cost. Wet-lab confirmation remains necessary for pre-clinical ADME/Tox predictions, although quantum-enabled free-energy estimation is helping shorten validation cycles.

North America Maintains Leadership as Asia-Pacific Records Fastest Growth

North America generated 47.76% of global computational drug discovery market revenue in 2025. The region benefits from deep venture capital networks, a high concentration of pharmaceutical headquarters, advanced cloud infrastructure, and early regulatory engagement. FDA initiatives, including model-informed paired meetings and Project Optimus, have increased confidence in algorithm-supported submissions and strengthened the region's position as the largest commercial market.

Asia-Pacific is projected to record the fastest growth, with a CAGR of 17.34%. China, India, and Japan are investing in sovereign AI infrastructure and more efficient drug approval pathways. China accounts for approximately one-third of the global innovation pipeline and increasingly runs parallel in-silico and wet-lab campaigns, reducing hit-to-IND timelines to 18 months. India's Peptris capital raise and Japan's Ono-Congruence partnership in 2026 also demonstrate growing regional capabilities in peptide and biophysics-driven discovery.

Europe remains supported by leading academic consortia and EMA acceptance of digital-biology evidence, although lower venture funding and regulatory fragmentation can limit scale. The Middle East & Africa and South America are earlier-stage markets, but adoption is increasing as local contract research organizations use cloud SaaS platforms to address high-performance computing constraints.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Escalating R&D Cost Pressures Driving Adoption of In-Silico Platforms

4.2.2 Rapid Advances in AI/ML and Generative Chemistry Algorithms

4.2.3 Cloud/Saas Delivery Models Lowering Entry Barriers

4.2.4 Regulatory Embrace of Model-Informed Drug Development (MIDD) Guidelines

4.2.5 Quantum Computing Breakthroughs Enabling Sub-Hour Free-Energy Calculations

4.2.6 Patient Digital-Twin Integration Fuelling In-Silico Trial Simulation Demand

4.3 Market Restraints

4.3.1 High Upfront HPC and Specialized-Talent Requirements

4.3.2 Data Silos and Poor Interoperability Across Multi-Omics Datasets

4.3.3 Regulatory Pushback on Explainability of AI-Designed Molecules

4.3.4 GPU/Compute Supply-Chain Crunch Limiting Capacity 2026-2029

4.4 Value-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Component

5.1.1 Software / AI platforms

5.1.2 Services

5.2 By Workflow

5.2.1 Target Identification and Validation

5.2.2 Lead Discovery

5.2.3 Lead Optimization

5.2.4 Pre-clinical ADME/Tox Prediction

5.2.5 Others

5.3 By End-user

5.3.1 Pharmaceutical and Biotechnology Companies

5.3.2 Contract Research Organizations (CROs)

5.3.3 Academic and Research Institutes

5.4 By Technology

5.4.1 Structure-Based Drug Design (SBDD)

5.4.2 Ligand-Based Drug Design (LBDD)

5.4.3 AI / Generative-AI Platforms

5.4.4 Molecular Dynamics and Simulation

5.4.5 Quantum / Accelerated Computing

5.5 By Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 United Kingdom

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)

6.3.1 Atomwise Inc.

6.3.2 BenevolentAI

6.3.3 BioSolveIT GmbH

6.3.4 Certara USA Inc.

6.3.5 Charles River Laboratories

6.3.6 Cloud Pharmaceuticals

6.3.7 Cresset

6.3.8 Cyclica Inc.

6.3.9 Dassault Systemes

6.3.10 Deep Genomics

6.3.11 Evotec SE

6.3.12 Exscientia plc

6.3.13 Iktos

6.3.14 Insilico Medicine

6.3.15 NVIDIA

6.3.16 Optibrium Ltd.

6.3.17 Recursion Pharmaceuticals

6.3.18 Schrodinger Inc.

6.3.19 Simulations Plus Inc.

6.3.20 XtalPi Inc.

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/nqbyn7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.